SCHEMBL148354

SCHEMBL148354

NC(=O)c1c(-c2ccnc3ccccc23)ccc2c1[nH]c1ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.45
PIM3 Q86V86 1/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
MAPK1 P28482 2/20 0.45
HSD17B10 Q99714 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
PARP14 Q460N5 1/20 0.44
DYRK1A Q13627 1/20 0.43
BCHE P06276 1/20 0.42
IDO1 P14902 1/20 0.42
MAPT P10636 2/20 0.42
TDO2 P48775 2/20 0.42
MEN1 O00255 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148605 0.94 PIM1 (0.44) PIM1PIM3KDM4EALDH1A1HPGD
SCHEMBL149085 0.79 BCHE (0.46) PIM1PIM3PARP14DYRK1ABCHE
SCHEMBL147833 0.78 PIM3 (0.50) PIM1PIM3KDM4EALDH1A1PARP14
SCHEMBL148467 0.77 TDO2 (0.54) PIM1PIM3PARP14IDO1MAPT
SCHEMBL7723752 0.75 PIM3 (0.47) PIM1PIM3KDM4EALDH1A1PARP14
SCHEMBL27991327 0.73 NUDT1 (0.61) KDM4EALDH1A1HPGDMAPK1HSD17B10
SCHEMBL28165763 0.72 PIM3 (0.55) PIM1PIM3KDM4EALDH1A1MAPK1
SCHEMBL29611964 0.72 BRAF (0.61) PIM1PIM3KDM4EALDH1A1HPGD
SCHEMBL1218770 0.72 BRAF (0.61) PIM1PIM3KDM4EALDH1A1HPGD
SCHEMBL29832015 0.71 KIF11 (0.55) KDM4EALDH1A1HPGDMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PIM1 90/4885PIM3 102/4885KDM4E 733/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PIM1 90/4885PIM3 102/4885KDM4E 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.